HCAT - Health Catalyst, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
37.02
+1.69 (+4.78%)
At close: 4:00PM EDT

36.90 -0.12 (-0.32%)
After hours: 4:03PM EDT

Stock chart is not supported by your current browser
Previous Close35.33
Open35.13
Bid36.80 x 1200
Ask37.40 x 1000
Day's Range34.91 - 37.24
52 Week Range32.15 - 49.85
Volume320,982
Avg. Volume588,811
Market Cap1.351B
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-58.74
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est51.00
Trade prices are not sourced from all markets
  • Interested in Health Catalyst? Be a Patient Buyer
    TheStreet.com

    Interested in Health Catalyst? Be a Patient Buyer

    Health Catalyst is a new issue. What do they do? HCAT "is a mission-driven data warehousing, analytics and outcomes-improvement company that helps healthcare organizations". One caller during Jim Cramer's Mad Money Lightning Round inquired about it - "Wait for it to come down, that is a great company," said Cramer.

  • GlobeNewswire

    Health Catalyst Reports Second Quarter 2019 Results

    SALT LAKE CITY, Aug. 22, 2019 -- Health Catalyst, Inc. (Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today.

  • MarketWatch

    Health Catalyst's stock surges as Wall Street analysts unanimously start coverage with bullish ratings

    Shares of Health Catalyst Inc. ran up 5.0% in afternoon trading Monday, after the Wall Street analysts who started coverage of the health data and analytics company were unanimously bullish. The company went public on July 25 at an initial public offering price of $26. Since closing that day at $39.17, the stock has now rallied 14%. In comparison, the Renaissance IPO ETF has shed 6.1% over the same time and the S&P 500 has declined 2.6%. All 7 analysts surveyed by FactSet who started covering Health Catalyst have the equivalent of buy ratings, while the average price target of $50.67 is 14% above current levels. Analyst Anne Samuel at J.P. Morgan, who initiated the company at overweight with a $50 stock price target, said Health Catalyst has less than 5% penetration of an $8 billion addressable market, "leaving significant runway for growth." SunTrust Robinson Humphrey's Sandy Draper started the company at buy with a $53 stock price target, citing an expected "long runway for growth," reinforced by an attractive revenue mix shift that should help improve gross margin as revenue grows.

  • PR Newswire

    Health Catalyst Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

    SALT LAKE CITY , July 30 , 2019 /PRNewswire/ -- Health Catalyst, Inc. ("Health Catalyst", Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, ...

  • PR Newswire

    Health Catalyst Announces Pricing of Initial Public Offering

    SALT LAKE CITY , July 25, 2019 /PRNewswire/ -- Health Catalyst, Inc. ("Health Catalyst", Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, ...

  • Benzinga

    Health Catalyst IPO: What You Need To Know

    Salt Lake City, Utah-based Health Catalyst, Inc. plans to offer 7 million shares in an IPO to be priced between $24 and $25, according to a S-1/Afiling done on July 23. The company upsized the offering from the initially planned 6 million share as well as hiked the estimated price range from $20 to $23. The company's shares have been approved for listing on the Nasdaq under the ticker symbol HCAT.

  • Benzinga

    IPO Outlook For The Week: Biotech, Health Analytics, Sports And Solar Power

    For a more comprehensive IPO calendar, check out the offering in Benzinga Cloud . The IPO dates below are expected but not confirmed. Castle Biosciences Inc (NASDAQ: CSTL ) will issue more than 3.33 million ...